Puma Biotechnology Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing

NEW YORK, June 1, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for Puma Biotechnology shareholders (NYSE:PBYI). Concerned PBYI investors who purchased these stocks are encouraged to contact securities attorney Hamilton Lindley by clicking here.

Puma announced, on July 22, 2014, positive top line results from the Phase III clinical trial of its investigational breast cancer, PB272 (neratinib). Based on these results, Puma stated that it plans to file for regulatory approval of neratinib in the first half of 2015, a claim that was confirmed as recently as November 13, 2014.

Puma then announced on December 2, 2014 that the submission for regulatory approval would be delayed until the first quarter of 2016. Puma originally said it would apply to use neratinib for HER2-positive metastatic breast cancer, a sicker, higher-risk group, and now plans to apply first for extended adjuvant HER2-positive early stage breast cancer.

Then on May 14, 2015, Puma's shares fell after reporting results from a study of their breast cancer drug. While 93.9 percent of the patients taking the drug combination were still alive two years later, it was not substantially better than the 91.6 percent of patients who were treated with only Herceptin and chemotherapy.

On this news, shares of Puma fell $38.87 or 18.53% during intraday trading to trade at $170.85 on May 14, 2015.

Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. PBYI stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/PBYI.  

Find these Waco business attorneys on social media on Google+, LinkedIn, Facebook, and Twitter.

SOURCE Dunnam & Dunnam

Related Links

http://www.dunnamlaw.com